Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
9.62
+0.35 (3.78%)
At close: Aug 27, 2025, 4:00 PM
9.76
+0.14 (1.46%)
After-hours: Aug 27, 2025, 7:53 PM EDT
Evolent Health Revenue
Evolent Health had revenue of $444.33M in the quarter ending June 30, 2025, a decrease of -31.34%. This brings the company's revenue in the last twelve months to $2.20B, down -6.71% year-over-year. In the year 2024, Evolent Health had annual revenue of $2.55B with 30.09% growth.
Revenue (ttm)
$2.20B
Revenue Growth
-6.71%
P/S Ratio
0.51
Revenue / Employee
$487,982
Employees
4,500
Market Cap
1.12B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.55B | 590.85M | 30.09% |
Dec 31, 2023 | 1.96B | 611.88M | 45.26% |
Dec 31, 2022 | 1.35B | 444.06M | 48.91% |
Dec 31, 2021 | 907.96M | -16.68M | -1.80% |
Dec 31, 2020 | 924.64M | 237.52M | 34.57% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EVH News
- 6 days ago - Evolent's Soft Q2 Results: Why I'm Holding Anyway - Seeking Alpha
- 8 days ago - Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock - PRNewsWire
- 9 days ago - Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock - PRNewsWire
- 19 days ago - Evolent Health, Inc. (EVH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Evolent Announces Second Quarter 2025 Results - PRNewsWire
- 6 weeks ago - Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - PRNewsWire
- 7 weeks ago - Evolent announces key appointments to leadership team - PRNewsWire
- 2 months ago - Evolent reiterates Q2 and full year guidance for Adjusted EBITDA - PRNewsWire